Richard Nicholas

List of Publications by Citations

83 papers	3,879 citations	24 h-index	62 g-index
86 ext. papers	4,816 ext. citations	6.5 avg, IF	5.12 L-index

#	Paper	IF	Citations
83	Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. *Brain*, **2007**, 130, 1089-104	11.2	872
82	Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. *Brain*, **2011**, 134, 2755-71	11.2	531
81	A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. *Annals of Neurology*, **2010**, 68, 477-93	9.4	441
80	Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. *Lancet, The*, **2014**, 383, 2213-21	40	283
79	Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. *Brain*, **2012**, 135, 2925-37	11.2	238
78	The neuropathological basis of clinical progression in multiple sclerosis. *Acta Neuropathologica*, **2011**, 122, 155-70	14.3	148
77	Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 117-25	5.5	136
76	Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. *Annals of Neurology*, **2018**, 83, 739-755	9.4	129
75	COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	128
74	In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with (18)F-PBR111 PET. *Journal of Nuclear Medicine*, **2014**, 55, 1112-8	8.9	67
73	Extensive grey matter pathology in the cerebellum in multiple sclerosis is linked to inflammation in the subarachnoid space. *Neuropathology and Applied Neurobiology*, **2015**, 41, 798-813	5.2	62
72	Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. *Brain*, **2015**, 138, 110-9	11.2	60
71	Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study. *Neurobiology of Disease*, **2014**, 65, 203-10	7.5	54
70	The relationship of age with the clinical phenotype in multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 1750-1758	5	41
69	C-PBR28 and F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis. *Journal of Nuclear Medicine*, **2017**, 58, 1477-1482	8.9	36
68	Meningeal inflammation changes the balance of TNF signalling in cortical grey matter in multiple sclerosis. *Journal of Neuroinflammation*, **2019**, 16, 259	10.1	36
67	B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis. *Brain Pathology*, **2020**, 30, 779-793	6	33

66	Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis. *Multiple Sclerosis Journal*, **2019**, 25, 653-660	5	30
65	Anti-JC virus antibody titres increase over time with natalizumab treatment. *Multiple Sclerosis Journal*, **2015**, 21, 1833-8	5	28
64	Iron homeostasis, complement, and coagulation cascade as CSF signature of cortical lesions in early multiple sclerosis. *Annals of Clinical and Translational Neurology*, **2019**, 6, 2150-2163	5.3	28
63	Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter. *Molecular Imaging and Biology*, **2019**, 21, 935-944	3.8	27
62	A Comparison of Magnetization Transfer Methods to Assess Brain and Cervical Cord Microstructure in Multiple Sclerosis. *Journal of Neuroimaging*, **2017**, 27, 221-226	2.8	27
61	Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm. *Annals of Neurology*, **2020**, 88, 93-105	9.4	26
60	Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**,	5.5	25
59	Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis. *Neurology*, **2015**, 84, 1473-82	6.5	24
58	Programmed death 1 is highly expressed on CD8 CD57 T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus. *Immunology*, **2017**, 152, 660-676	7.8	22
57	Temporal lobe cortical pathology and inhibitory GABA interneuron cell loss are associated with seizures in multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 25-35	5	20
56	Associations of DMT therapies with COVID-19 severity in multiple sclerosis		20
55	Analysis of ageing-associated grey matter volume in patients with multiple sclerosis shows excess atrophy in subcortical regions. *NeuroImage: Clinical*, **2017**, 13, 9-15	5.3	18
54	Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis. *Multiple Sclerosis Journal*, **2017**, 23, 1469-1478	5	17
53	Bladder symptoms in multiple sclerosis: a review of pathophysiology and management. *Expert Opinion on Drug Safety*, **2010**, 9, 905-15	4.1	17
52	Remote Monitoring in the Home Validates Clinical Gait Measures for Multiple Sclerosis. *Frontiers in Neurology*, **2018**, 9, 561	4.1	15
51	A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK. *Journal of Medical Economics*, **2017**, 20, 474-482	2.4	14
50	Intrathecal Inflammation in Progressive Multiple Sclerosis. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	14
49	Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. *Wellcome Open Research*, **2016**, 1, 10	4.8	14

48	Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale-29. *PLoS Medicine*, **2017**, 14, e1002346	11.6	14
47	Lipoprotein markers associated with disability from multiple sclerosis. *Scientific Reports*, **2018**, 8, 17026	4.9	14
46	Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 11020-11027	11.5	13
45	COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. *Multiple Sclerosis and Related Disorders*, **2021**, 52, 102939	4	12
44	Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. *Wellcome Open Research*,1, 10	4.8	11
43	Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility. *Journal of Medical Economics*, **2017**, 20, 962-973	2.4	9
42	A realist review of advance care planning for people with multiple sclerosis and their families. *PLoS ONE*, **2020**, 15, e0240815	3.7	9
41	Accelerated brain ageing and disability in multiple sclerosis		9
40	Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis. *Current Medical Research and Opinion*, **2020**, 36, 1157-1166	2.5	8
39	Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register. *Multiple Sclerosis Journal*, **2021**, 13524585211020435	5	8
38	Breaking the cycle: Reversal of flux in the tricarboxylic acid cycle by dimethyl fumarate. *Neurology: Neuroimmunology and NeuroInflammation*, **2019**, 6, e562	9.1	7
37	Defective CD19+CD24CD38 transitional B-cell function in patients with relapsing-remitting MS. *Multiple Sclerosis Journal*, **2021**, 27, 1187-1197	5	7
36	Peripheral Nerve Dysfunction in Middle-Aged Subjects Born with Thalidomide Embryopathy. *PLoS ONE*, **2016**, 11, e0152902	3.7	6
35	Initiating disease-modifying treatments in multiple sclerosis: Measuring the decision process using decisional conflict and decisional regret scales. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2019**, 5, 2055217319833006	2	5
34	Progressive Dwindling in Multiple Sclerosis: An Opportunity to Improve Care. *PLoS ONE*, **2016**, 11, e0159210	3.7	5
33	Willingness to receive a COVID-19 vaccine in people with multiple sclerosis - UK MS Register survey. *Multiple Sclerosis and Related Disorders*, **2021**, 55, 103175	4	5
32	The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis. *Current Medical Research and Opinion*, **2020**, 36, 1145-1156	2.5	4
31	Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2018**, 5, e470	9.1	4

30	A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe. *Multiple Sclerosis and Related Disorders*, **2015**, 4, 83-4	4	4
29	Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series. *Neurology*, **2021**, 97, e890-e901	6.5	4
28	CSF parvalbumin levels reflect interneuron loss linked with cortical pathology in multiple sclerosis. *Annals of Clinical and Translational Neurology*, **2021**, 8, 534-547	5.3	4
27	[C]PBR-28 positron emission tomography in multiple sclerosis: Neuroinflammation or otherwise?. *Annals of Neurology*, **2017**, 81, 323-324	9.4	3
26	Natalizumab granule cell neuronopathy: FDG-PET in diagnosis and immune reconstitution with G-CSF. *Neurology: Neuroimmunology and NeuroInflammation*, **2017**, 4, e384	9.1	3
25	18F-GE180, a radioligand for the TSPO protein: not ready for clinical trials in multiple sclerosis. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 2242-2243	8.8	3
24	Using amyloid PET imaging to diagnose Alzheimer's disease in patients with multiple sclerosis. *Journal of Neurology*, **2020**, 267, 3268-3273	5.5	3
23	A Rapid Electronic Cognitive Assessment Measure for Multiple Sclerosis: Validation of Cognitive Reaction, an Electronic Version of the Symbol Digit Modalities Test. *Journal of Medical Internet Research*, **2020**, 22, e18234	7.6	3
22	The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab. *Neurology*, **2018**, 91, 572-573	6.5	3
21	Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis. *PLoS ONE*, **2017**, 12, e0169546	3.7	2
20	Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register. *Neurology: Neuroimmunology and NeuroInflammation*, **2022**, 9,	9.1	2
19	OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis. *BMJ Open*, **2021**, 11, e050176	3	2
18	In Response to Letter from Fregonara et al. 2019. *Molecular Imaging and Biology*, **2020**, 22, 13-14	3.8	2
17	Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients. *Multiple Sclerosis Journal*, **2021**, 13524585211032510	5	2
16	Multiple sclerosis. *Clinical Evidence*, **2007**, 2007,		2
15	BG-12 and its potential for the prevention of relapse in multiple sclerosis. *Degenerative Neurological and Neuromuscular Disease*, **2012**, 2, 119-132	5.4	1
14	Automated characterisation of microglia in ageing mice using image processing and supervised machine learning algorithms.. *Scientific Reports*, **2022**, 12, 1806	4.9	1
13	The impact of the face-to-face consultation on decisional conflict in complex decision-making in multiple sclerosis: A pilot study. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2020**, 6, 2055217320959802	2	1

12	COVID-19 is associated with multiple sclerosis exacerbations that are prevented by disease modifying therapies		1
11	Pre-existing anxiety, depression, and neurological disability is associated with long COVID: A prospective and longitudinal cohort of the United Kingdom Multiple Sclerosis Register		1
10	Worse Physical Disability Is Associated With the Expression of PD-1 on Inflammatory T-Cells in Multiple Sclerosis Patients With Older Appearing Brains.. *Frontiers in Neurology*, **2021**, 12, 801097	4.1	0
9	Investigation of the correlation between mildly deleterious mtDNA Variations and the clinical progression of multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2021**, 53, 103055	4	0
8	BRAIN VOLUME CHANGE AND DISABILITY IN FINGOLIMOD TRIALS. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, e4.44-e4	5.5	
7	INFLIXIMAB FOR REFRACTORY NEUROSARCOIDOSIS. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, A21.1-A21	5.5	
6	A realist review of advance care planning for people with multiple sclerosis and their families **2020**, 15, e0240815		
5	A realist review of advance care planning for people with multiple sclerosis and their families **2020**, 15, e0240815		
4	A realist review of advance care planning for people with multiple sclerosis and their families **2020**, 15, e0240815		
3	A realist review of advance care planning for people with multiple sclerosis and their families **2020**, 15, e0240815		
2	A realist review of advance care planning for people with multiple sclerosis and their families **2020**, 15, e0240815		
1	A realist review of advance care planning for people with multiple sclerosis and their families **2020**, 15, e0240815		